Compare GLAD & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GLAD | CGC |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.7M | 467.3M |
| IPO Year | 2001 | 2023 |
| Metric | GLAD | CGC |
|---|---|---|
| Price | $19.67 | $1.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $22.33 | N/A |
| AVG Volume (30 Days) | 165.1K | ★ 3.5M |
| Earning Date | 05-06-2026 | 05-29-2026 |
| Dividend Yield | ★ 9.78% | N/A |
| EPS Growth | ★ 91.82 | 84.17 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | $15.16 | $8.27 |
| Revenue Next Year | $5.10 | $15.68 |
| P/E Ratio | $19.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.54 | $0.84 |
| 52 Week High | $26.49 | $2.38 |
| Indicator | GLAD | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.49 | 65.70 |
| Support Level | $18.52 | $1.01 |
| Resistance Level | $20.23 | $1.08 |
| Average True Range (ATR) | 0.41 | 0.04 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 65.73 | 90.91 |
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.